A mathematical model of tumor-immune evasion and siRNA treatment

Discrete and Continuous Dynamical Systems - Series B

Volumn 4, Issue 1, 2004, Pages 39-58

  Arciero, J C ^a   Jackson, T L ^a   Kirschner, D E ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Immune response; Mathematical model; siRNA; Tumor

Indexed keywords

EID: 1042302664     PISSN: 15313492     EISSN: None     Source Type: Journal    
DOI: 10.3934/dcdsb.2004.4.39     Document Type: Conference Paper

References (26)

1. J.A. Adam and N. Bellomo. A survey of models for tumor-immune system dynamics. Birkhauser, Boston, 1996.
2. M.R. Bernsen, J. Tang, L.A. Everse, J.W. Koten, and W. Den Otter. Interleukin 2 (IL-2) therapy: potential advantages of locoregional versus systemic administration. Cancer Treat. Rev., 25:73-82, 1999.
3. N.J. Caplen, S. Parrish, F. Imani, A. Fire, and R.A. Morgan. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc. Natl. Acad. Sci., 98:9742-9747., 2001.
4. A. Cerwenka and S.L. Swain. TGF-β1: Immunosuppressant and viability factor for T lymphocytes. Microbes Infec., 1:1291-1296., 1999.
5. A.E. Chang and S. Shu. Current status of adoptive immunotherapy of cancer. Crit. Rev. Oncol. Hematol., 22:213-228, 1996.
6. K.E. de Visser and W.M. Kast. Effects of TGF-β on the immune system: Implications for cancer immunotherapy. Leukemia, 13:1188-1199, 1999.
7. R.J. DeBoer, P. Hogeweg, H.F.J Dullens, R.A. De Weger, and W. Den Otter. Macrophage T lymphocyte interactions in the anti-tumor immune response: A mathematical model. J. Immunol., 134:2748-2757, 1985.
8. S. Elbashir, J. Harborth, W. Lendeckel, A. Yalcin, K. Weber, and T. Tuschl. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature., 411:494-498, 2001.
9. I. Espinoza-Delgado, M.C. Bosco, T. Mussso, K. Mood, F.W. Ruscetti, D.L. Longo, and L. Varesio. Inhibitory cytokine circuits involving transforming growth factor-β, interferon-γ, and interleukin-2 in human monocyte activation. Blood, 83:3332-3338., 1994.
10. J. Folkman and M. Hochberg. Self-regulation of growth in three dimensions. J. Exp. Med., 138:743., 1973.
11. T. Holen, M. Amarzguioui, M.T. Wiiger, E. Babaie, and H. Prydz. Positional effects of short interfering RNAs targeting the human coagulation trigger tissue factor. Nucleic Acids Res., 30:1757-1766, 2002.
12. C.I. Hsieh, D.S. Chen, and L.H. Hwang. Tumor-induced immunosuppression: A barrier to immunotherpay of large tumors by cytokine-secreting tumor vaccine. Hum. Gene Ther., 11:681-692, 2000.
13. D. Kirschner and J.C. Panetta. Modeling immunotherapy of the tumor-immune interaction. J. Mathem. Biol., 37:235-252, 1998.
14. V.A. Kuznetsov and I.A. Makalkin. Nonlinear dynamics of immunogenic tumors: Parameter estimation and global bifurcation analysis. Bullet. Mathem. Biol., 56:295-321, 1994.
15. C. Lipardi, Q. Wei, and B.M. Paterson. RNAi as random degradative PCR: siRNA primers convert mRNA into dsRNAs that are degraded to generate new siRNAs. Cell, 107:297-307., 2001.
16. X.W. Mao, J.D. Kettering, and D.S. Gridley. Immunotherapy with low-dose interleukin-2 and anti-transforming growth factor-β antibody in a murine tumor model. Cancer Biother., 9:317-325, 1994.
17. 3H]-thymidine incorporation in CD3ε mAb- and CD28 mAb-activated splenocytes and thymocytes. Immunopharmacology, 48:101-115, 2000.
18. M.A. Nash, G. Ferrandina, M. Gordinier, A. Loercher, and R.S. Freedman. The role of cytokines in both the normal and malignant ovary. Endoc. Rel. Cancer, 6:93-107., 1999.
19. A. Nykanen, B. Haley, and P.D. Zamore. ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell, 107:309-321., 2001.
20. F. Paillard. Immunosuppression mediated by tumor cells: A challenge for immunotherapeutic appraoaches. Hum. Gene Ther., 11:657-658, 2000.
21. G. Storz. An expanding universe of noncoding RNAs. Science, 296:1260-1263, 2002.
22. T. Tuschl. Expanding small RNA interference. Nature Biotech., 20:446-448, 2002.
23. T.S. Tzai, A.L. Shiau, L.L. Liu, and C.L. Wu. Immunization with TGF-β antisense oligonucleotide-modified autologous tumor vaccine enhances the antitumor immunity of MBT-2 tumor-bearing mice trough upregulation of MHC Class I and Fas expressions. Anitcancer Res., 20:1557-1562, 2000.
24. F. Wianny and M. Zernicka-Goetz. Specific interference with gene function by double-stranded RNA in early mouse development. Nature Cell Biol., 2:70-75, 2000.
25. S. Wojtowicz-Praga. Reversal of tumor-induced immunosuppression: A new approach to cancer therapy. J. Immunol., 20:165-177, 1997.
26. P.D Zamore. Ancient pathways programmed by small RNAs. Science, 296:1265-1269, 2002.